目的:观察复方口服避孕药( COCs)妈富隆(去氧孕烯/炔雌醇)对青春期女性骨矿物质密度(BMD)的影响.方法:接纳150例年龄16～18岁女性应用COCs避孕为观察组,用药24个月；接纳150例年龄16 ～18岁从未应用激素避孕药女性做对照组；应用双能X-线吸收法测量腰椎和股骨颈BMD.结果:观察组用药2年后腰椎和股骨颈BMD从基础值1.010±0.107g/cm3和0.818 +0.089g/cm3降低到1.007±0.108g/cm3和0.813±0.090g/cm3,分别降低了0.29％和0.61％；而对照组则从基础值1.008±0.109g/cm3和0.816±0.087g/cm3增高至1.027±0.106g/cm3和0.824±0.089g/cm3,分别增高了1.88％和0.98％；用药2年后,观察组与对照组相比BMD无明显差异(P＞0.05).结论:青春期女性应用COCs避孕2年对BMD无明显影响.%Objective: To compare adole§cents'bone mineral density (BMD) between users of Marvelon ( desogegtrel/ethi-nyleslradiol) and control women. Methods; A total of 150 women aged between 16 and 18 years usd Marvelon for 24 months (the study group) and 150 women aged between 16 and 18 years using nonhoimonal contraception were as the control. BMD at both lumbar spine and femora] neck sites were evaluated by dual - energy X -ray absorptiometry. Results; After 24 months of Marvelon oral administration, as compared to baseline, the mean BMD in lumbar spine and femoral neck were decreased by 0.29% and 0. 619fc , respectively. While in the control group, the mean BMD at both sites were increased by 1. 88% and 0. 98% , respectively. There were no significant differences in BMD at both lumbar spine and femoral neck sites between the two groups (P>0.05). Conclusion; Two years of Marvelon use had no significant effect on bone density in adolescents.
展开▼
